Form D · Biotechnology
GLIAMED INC
Framingham, MA · CIK 0001440513
Offering snapshot reported May 4, 2009 · SEC filing
- Reported sold
- $2.47M Offering amount: $28.9M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 4, 2009 | Initial | $2,465,737 | No comparison | Not reported | SEC filing |
| Oct 28, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 14, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-120434
Source: Form D, filed May 4, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Andrew Busser | Director |
| Barry Dickman | Director |
| Andrew Uprichard | Director, Executive |
| David Weinstein | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
495 Old Connecticut Path, Suite 320
Framingham, MA, 01701
Framingham, MA, 01701